前列腺腺癌患者循环血中DC123 +（淋巴样）和DC11C +（髓样）树突状细胞亚群的特征分析

Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.

作者信息

Sciarra Alessandro, Lichtner Miriam, Autran Gomez AnnaMaria, Mastroianni Claudio, Rossi Raffaella, Mengoni Fabio, Cristini Cristiano, Gentilucci Alessandro, Vullo Vincenzo, Di Silverio Franco

机构信息

Department of Urology, University of La Sapienza, Rome, Italy.

出版信息

Prostate. 2007 Jan 1;67(1):1-7. doi: 10.1002/pros.20431.

DOI:10.1002/pros.20431

PMID:17075798

Abstract

PURPOSE

We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count.

METHODS

Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs).

RESULTS

We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively).

CONCLUSIONS

We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease.

摘要

目的

我们验证了前列腺腺癌是否会对树突状细胞（DC）亚群计数产生特定改变。

方法

将21例未经治疗的前列腺腺癌根据临床分期分为局限性疾病组和转移性疾病组。作为对照，我们使用了18名健康男性受试者。对于DC计数，所有病例均采集外周血（PB）样本。基于Tru-COUNT的单平台流式细胞术检测用于计数两种DC亚群，即髓样（mDCs）和浆细胞样（pDCs）。

结果

与健康对照组相比，我们发现前列腺癌患者群体中的pDCs计数有统计学意义的降低（P = 0.002）。将每个临床阶段与健康对照组进行比较，对照组与转移组在pDCs和mDCs方面均存在显著差异（分别为P = 0.005和P = 0.023），但对照组与局限性疾病组之间无显著差异（分别为P = 0.055和P = 0.829）。